NCT07439133招募中3 期
Evaluation of the Efficacy and Safety of XTR004 Injection in Detecting Blood Flow Restrictive Stenosis in Patients With Suspected or Known Stable Coronary Artery Disease: A Multicenter, Open-Label, Phase III Clinical Trial
Sinotau Pharmaceutical Group5 个研究点 分布在 1 个国家目标入组 395 人开始时间: 2025年11月14日最近更新:
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 395
- 试验地点
- 5
- 主要终点
- Diagnostic Efficacy of XTR004 PET myocardial perfusion imaging (MPI) for detecting restrictive stenosis, using quantitative coronary angiography (QCA) and fractional flow reserve (FFR) as reference standards
研究概览
简要总结
The primary objective of this study is to evaluate the effectiveness of visual reading in XTR004 PET myocardial perfusion imaging (MPI) for detecting restrictive stenosis, using quantitative coronary angiography (QCA) and fractional flow reserve (FFR) as reference standards in patients with suspected or known coronary artery disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants aged 18 to 80 years, male or female.
- •Suspected or confirmed patients with stable coronary heart disease. Those suspected of having stable coronary heart disease must meet at least one of the following risk factors: hypertension, hyperlipidemia, diabetes, obesity (BMI ≥28), a history of alcohol abuse, a smoking history, a family history of coronary heart disease, postmenopausal status, or age 60 years or older.
- •Participants can communicate well with investigators, understand and comply with clinical trial requirements, voluntarily participate in the study, and sign an informed consent form.
排除标准
- •Participants with severe cardiovascular diseases, including but not limited to unstable angina (Canadian Cardiac Society (CCS) Grade III/IV angina pectoris), uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg and/or diastolic ≥110 mmHg despite long-term regular antihypertensive medication), hypotension (resting systolic blood pressure <90 mmHg), acute myocardial infarction, second or third-degree atrioventricular block, sinoatrial node disease, NYHA Class III/IV heart failure, dilated or hypertrophic cardiomyopathy, pericarditis, valvular heart disease, aortic dissection, uncontrolled severe arrhythmias, congenital heart disease, those who have undergone coronary artery bypass grafting or interventional procedures within three months, and those determined unsuitable for participation in this study by investigators;
- •Participants with severe acute or chronic pulmonary diseases (including but not limited to COPD, asthma, bronchiectasis, emphysema, pulmonary fibrosis, pulmonary embolism, pneumonia, etc.) who are determined unsuitable for participation by the investigator;
- •Participants with severe or unstable central nervous system disorders (including but not limited to unstable cerebrovascular diseases, active epilepsy, CNS infections, CNS diseases accompanied by mental disorders or motor impairments) who are determined unsuitable for participation by the investigator;
- •Participants with severe bleeding disorders or coagulation dysfunction (including but not limited to purpura, hemophilia, vitamin K deficiency, etc.) who are determined unsuitable for participation by the investigator;
- •Participants with severe liver dysfunction (including but not limited to viral hepatitis, autoimmune hepatitis, cirrhosis, liver cancer, etc.) who are determined unsuitable for participation by the investigator;
- •Participants with severe kidney impairment (including but not limited to glomerulonephritis, renal insufficiency, nephrotic syndrome, membranous nephropathy, hydronephrosis, renal cystopathy, etc.) who are determined unsuitable for participation by the investigator;
- •Participants with fever or active infectious diseases who are determined unsuitable for participation by the investigator;
- •Participants with known alcohol allergy who are determined unsuitable for participation by the investigator;
- •participants with known adenosine allergy who are determined unsuitable for participation by the investigator;
- •Participants with known iodine contrast agent allergy who are determined unsuitable for participation by the investigator;
- •Within the past 10 years, significant occupational exposure to ionizing radiation (e.g., exceeding 50 mSv/year) or exposure to radioactive substances or ionizing radiation for therapeutic/research purposes;
- •Male or women of childbearing age not using effective contraception during study participation and within 6 months post-study (effective contraception refers to sterilization, intrauterine device, condoms, abstinence, or surgical blockage of vas deferens/fallopian tubes);
- •Female participants in pregnancy or lactation
- •Individuals with claustrophobia, bipolar disorder, mental disorders, or poor compliance;
- •Participation in other investigational drug trials within 30 days prior to enrollment or planned during study;
- •Any other circumstances determined unsuitable by investigators.
研究组 & 干预措施
enrolled participants with suspected or known CAD
Experimental
干预措施: XTR004 (Drug)
结局指标
主要结局
Diagnostic Efficacy of XTR004 PET myocardial perfusion imaging (MPI) for detecting restrictive stenosis, using quantitative coronary angiography (QCA) and fractional flow reserve (FFR) as reference standards
时间窗: 60 days
Sensitivity and specificity of XTR004 PET myocardial perfusion imaging (MPI) for detecting restrictive stenosis, using quantitative coronary angiography (QCA) and fractional flow reserve (FFR) as reference standards
次要结局
- To evaluate the differences in diagnostic efficacy between XTR004 PET MPI and MIBI SPECT MPI in detecting restrictive stenosis(60 days)
- To assess differences in image quality and diagnostic certainty between XTR004 PET MPI and MIBI SPECT MPI(60 days)
- To validate the effectiveness of semi-quantitative analysis in XTR004 PET MPI for the detection of restrictive stenosis(60 days)
- To evaluate the diagnostic efficacy of XTR004 PET MPI in different subgroups(60 days)
- To compare the differences in diagnostic performance between XTR004 PET MPI and MIBI SPECT MPI using QCA results as a reference standard(60 days)
- Number of participants with treatment-related adverse events, severe adverse events as assessed by CTCAE v5.0(60 days)
研究者
研究点 (5)
Loading locations...
相似试验
招募中
1 期
Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's SyndromeNCT07350707Peking Union Medical College Hospital160
尚未招募
1 期
Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular CarcinomaNCT07352345Union Hospital, Tongji Medical College, Huazhong University of Science and Technology150
已完成
不适用
CXCR4 PET/CT for Predicting Outcome in Limited-Stage Small Cell Lung CancerSmall Cell Lung CancerNCT07316309Shandong Cancer Hospital and Institute33
招募中
2 期
PET-Based Imaging of Radiolabeled CIT-0132025-522189-60-00Citryll B.V.12
招募中
不适用
Four-Timepoint Multi-tracer PET Imaging to Characterize Metastatic prOstate Cancer HeterogeneityNCT07302763Frederic Pouliot45